FCX-007

· Castle Creek Biosciences, LLC

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for FCX-007, covering 2021-09-16 to 2024-04-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa [Phase 3]